Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
EIU-104101 trial: what clinicians have said so far
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
- NCT07217171 ↗
- Recruiting
- EvolveImmune United, Inc
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on EIU-104101 (EVOLVE104 in advanced urothelial and squamous cell carcinomas) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EIU-104101 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 Dose-Escalation and Expansion Study Evaluating the Safety, Efficacy, and Pharmacokinetics of EVOLVE104 in Subjects With Advanced Urothelial and Squamous Cell Carcinomas
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Bladder Cancer; Squamous Cell Carcinoma of the Lung; Esophageal Squamous Cell Carcinoma; Tongue Squamous Cell Carcinoma; Cutaneous Squamous Cell Cancer; Penile Squamous Cell Carcinoma; Anal Squamous Cell Carcinoma; Vulvar Squamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Vaginal Squamous Cell Carcinoma; Urethral Squamous Cell Carcinoma
- Interventions
- EVOLVE104; EVOLVE104
- Arms
- Phase 1a Cohort 1; dose level 1 · Experimental
- Phase 1a Cohort 2; dose level 2 · Experimental
- Phase 1a Cohort 3; dose level 3 · Experimental
- Phase 1a Cohort 4; dose level 4 · Experimental
- Phase 1a Cohort 5; dose level 5 · Experimental
- Phase 1a Cohort 6; dose level 6 · Experimental
- Phase 1a Cohort 7; dose level 7 · Experimental
- Phase 1a Cohort 8; dose level 8 · Experimental
- Phase 1a Cohort 9; dose level 9 · Experimental
- Phase 1a Cohort 10; dose level 10 · Experimental
- Phase 1b Cohort 1; dose level TBD · Experimental
- Phase 1b Cohort 2; dose level TBD · Experimental
- Enrollment
- 160 (estimated)
- Primary outcomes
- Incidence and Severity of Treatment Emergent Adverse Events (TEAEs)
- Number of patients with Dose Limiting Toxicities (DLTs)
- To determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDEs) for EVOLVE104
- To determine the recommended phase 2 dose (RP2D) of EVOLVE104
- Sponsor
- EvolveImmune United, Inc
- Start
- Nov 13, 2025
- Primary completion
- Jan 29, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT07217171 · updated Sep 15, 2026